| Product Name | Suvorexant - API |
| Product Code | DA-S189-a |
| Chemical name | Suvorexant |
| Synonyms | [(7R)-4-(5-Chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]-methanone; 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; [(R)-4-(5-Chloro-benzooxazol-2-yl)-7-methyl-[1,4]diazepan-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone; |
| Impurity | NA |
| CAS Number | 1030377-33-3 |
| Alternate CAS # | NA |
| Molecular form | C23H23ClN6O2 |
| Appearance | White to Pale Beige Solid |
| Melting Point | NA |
| Mol. Weight | 450.93 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,intermediates,pharmaceutical standards,fine chemicals |
| Boiling Point | NA |
| Applications | Suvorexant is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
